Total Funding
26
43
Total FundingVenture - Series Unknown raised
Growth Score
1 pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
61921
Heptares Therapeutics develops novel, small-molecule drugs for G-protein-coupled receptors (GPCRs).
Acquired by 
Sosei Group
- Daniel Grau: President
Malcolm Weir: Founder & CEOPast Role: Imperial College London, Visiting Professor of Biochemistry
About the Company
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.
The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, Stabilised
Receptors), overcoming a major limiting factor to the development of new drugs targeting this group.
